Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD
- Address
- lock Available on a paid plan
Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD
The Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD is a comprehensive neurological and psychiatric research center specializing in a broad spectrum of central nervous system disorders. The facility demonstrates particular expertise in multiple sclerosis research, conducting extensive investigations across relapsing-remitting, primary progressive, and secondary progressive forms of the disease, utilizing cutting-edge immunomodulatory therapies and monoclonal antibodies.
- Multiple Sclerosis: Comprehensive evaluation of disease-modifying therapies including ocrelizumab, ofatumumab, fenebrutinib, frexalimab, and remibrutinib across all MS subtypes
- Epilepsy and Seizure Disorders: Drug-resistant focal onset seizures, stereotypical prolonged seizures, and novel antiepileptic drug formulations
- Neurodegenerative Disorders: Parkinson's disease treatment development and Alzheimer's disease cognitive decline intervention studies
- Peripheral Neuropathies: Chronic inflammatory demyelinating polyneuropathy (CIDP) and immune-mediated neurological conditions
The center's research portfolio encompasses both pediatric and adult populations, with particular emphasis on long-term safety and efficacy studies. Their expertise extends to advanced neuroimaging techniques for monitoring disease progression, pharmacokinetic evaluations, and patient-reported outcome assessments. The facility's participation in international multi-center trials demonstrates its commitment to advancing treatment options for patients with relapsing and progressive neurological disorders, while maintaining focus on immune system diseases affecting the nervous system.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 86 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 86 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Xenon Pharmaceuticals Inc.3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG8trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD
lock Showing 1 of 47 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 86 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 8 | Unknown | 2018-07-25 | 2025-09-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.